We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Protein Imbalance Linked to Presence of Biomarker in Tears of Sjögren’s Syndrome Patients

By LabMedica International staff writers
Posted on 17 May 2016
Increased expression of cathepsin S (CTSS) activity has emerged as a unique biomarker in the tears of Sjögren’s syndrome (SS) patients.

Sjögren’s syndrome, which affects mainly women, is an autoimmune disease caused by immune cells attacking the mucous membrane and fluid-secreting glands. More...
Although its characteristic symptoms are in the eyes and mouth, the disease is systemic and can damage other organs including kidney, liver, and brain. Patients with SS also have a higher risk of developing lymphoma.

Investigators at the University of Southern California (Los Angeles, USA) had previously identified increased CTSS activity as a unique characteristic of SS patient tears. Cathepsin S is a lysosomal enzyme that belongs to the papain family of cysteine proteases. While a role in antigen presentation has long been recognized, it is now understood that CTSS has a role in itch and pain, or nociception. The nociceptive activity results from CTSS functioning as a signaling molecule via activation of protease-activated receptors.

In the current study, the investigators evaluated the role of the proteins Rab3D, Rab27a, and Rab27b in the enhanced release of CTSS from cells in the tear glands (lacrimal gland acinar cells or LGAC).

In this study, the investigators worked with mice that had been genetically engineered to lack the gene for production of one or more of the Rab proteins. They reported in the April 13, 2016, online edition of the journal American Journal of Physiology—Cell Physiology that mice lacking the gene Rab3D had more cathepsin S in their tears while mice lacking Rab27 had less. The activities of Rab3D and Rab27 counteracted each other, and loss of Rab3D seemed to increase the influence of Rab27, contributing to the release of cathepsin S in the tears of patients with SS.

“We think that the large increase in tear cathepsin S is a fairly robust biomarker for Sjögren’s syndrome-mediated dry eye,” said senior author Dr. Sarah F.Hamm-Alvarez, professor of ophthalmology at the University of Southern California. “Earlier detection and treatment would offer the potential to prevent some of these serious systemic effects and the opportunity to prevent serious damage and loss of glandular tissue beyond repair.”

Related Links:
University of Southern California


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
HPV Molecular Test
BD Onclarity HPV Assay
New
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.